The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.kint.2020.05.033 | DOI Listing |
Publication Analysis
Top Keywords
stop-igan trial
12
long-term outcomes
8
outcomes stop-igan
8
iga nephropathy
8
immunosuppression iga
4
iga nephropathy?
4
nephropathy? long-term
4
trial role
4
role immunosuppression
4
immunosuppression management
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!